Department of Radiology, Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, China.
Department of Pathology, Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, China.
Br J Radiol. 2020 Oct 1;93(1114):20200131. doi: 10.1259/bjr.20200131. Epub 2020 Aug 12.
Comparing the prediction models for the ISUP/WHO grade of clear cell renal cell carcinoma (ccRCC) based on CT radiomics and conventional contrast-enhanced CT (CECT).
The corticomedullary phase images of 119 cases of low-grade (I and II) and high-grade (III and IV) ccRCC based on 2016 ISUP/WHO pathological grading criteria were analyzed retrospectively. The patients were randomly divided into training and validation set by stratified sampling according to 7:3 ratio. Prediction models of ccRCC differentiation were constructed using CT radiomics and conventional CECT findings in the training setandwere validated using validation set. The discrimination, calibration, net reclassification index (NRI) and integrated discrimination improvement index (IDI) of the two prediction models were further compared. The decision curve was used to analyze the net benefit of patients under different probability thresholds of the two models.
In the training set, the C-statistics of radiomics prediction model was statistically higher than that of CECT ( < 0.05), with NRI of 9.52% and IDI of 21.6%, both with statistical significance ( < 0.01).In the validation set, the C-statistics of radiomics prediction model was also higher but did not show statistical significance ( = 0.07). The NRI and IDI was 14.29 and 33.7%, respectively, both statistically significant ( < 0.01). Validation set decision curve analysis showed the net benefit improvement of CT radiomics prediction model in the range of 3-81% over CECT.
The prediction model using CT radiomics in corticomedullary phase is more effective for ccRCC ISUP/WHO grade than conventional CECT.
As a non-invasive analysis method, radiomics can predict the ISUP/WHO grade of ccRCC more effectively than traditional enhanced CT.
比较基于 CT 影像组学和常规增强 CT(CECT)的肾透明细胞癌(ccRCC)ISUP/WHO 分级预测模型。
回顾性分析 119 例基于 2016 年 ISUP/WHO 病理分级标准的低级别(I 和 II 级)和高级别(III 和 IV 级)ccRCC 的皮质髓质期图像。患者按分层抽样法以 7:3 的比例随机分为训练集和验证集。在训练集中构建基于 CT 影像组学和常规 CECT 特征的 ccRCC 分化预测模型,并在验证集中验证。进一步比较两种预测模型的判别能力、校准能力、净重新分类指数(NRI)和综合判别改善指数(IDI)。使用两种模型在不同概率阈值下的患者净收益分析决策曲线。
在训练集中,影像组学预测模型的 C 统计量明显高于 CECT( < 0.05),NRI 为 9.52%,IDI 为 21.6%,均有统计学意义( < 0.01)。在验证集中,影像组学预测模型的 C 统计量也较高,但无统计学意义( = 0.07)。NRI 和 IDI 分别为 14.29%和 33.7%,均有统计学意义( < 0.01)。验证集决策曲线分析表明,在 3%至 81%的范围内,CT 影像组学预测模型的净收益优于 CECT。
皮质髓质期 CT 影像组学预测模型比常规 CECT 对 ccRCC ISUP/WHO 分级更有效。
作为一种非侵入性分析方法,影像组学比传统增强 CT 能更有效地预测 ccRCC 的 ISUP/WHO 分级。